PGN EDO53
Alternative Names: PGN-EDO53Latest Information Update: 13 Mar 2024
At a glance
- Originator Pepgen Corporation
- Class Antisense oligonucleotides; Drug conjugates; Morpholines; Peptide drug conjugates
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Duchenne muscular dystrophy
Most Recent Events
- 06 Mar 2024 PepGen plans to submit an Investigational New Drug (IND)/Clinical Trial Application (CTA) for Duchenne muscular dystrophy
- 14 Nov 2022 Pharmacodynamics data from preclinical studies in Duchenne muscular dystrophy released by PepGen
- 10 Nov 2022 Preclinical trials in Duchenne muscular dystrophy in USA (IV)